Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer.
Kyoung-Ho PyoSun Min LimChae-Won ParkHa-Ni JoJae Hwan KimMi-Ran YunDohee KimChun-Feng XinWongeun LeeBianca GheorghiuMin Hee HongHye Ryun KimHyo Sup ShimMi JangSung Sook LeeByoung Chul ChoPublished in: Journal for immunotherapy of cancer (2021)
ALK-positive tumors progressing on ceritinib is not immunogenic enough to respond to immune checkpoint inhibitors.